Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18676396 | ATROPINE-CONTAINING AQUEOUS COMPOSITION | May 2024 | December 2025 | Abandon | 18 | 2 | 0 | No | No |
| 18598292 | WOOD TREATMENT SOLUTIONS CONTAINING FUNGICIDES AND TERTIARY ALKANOLAMINES AND RELATED METHODS, WOOD PRODUCTS AND COMPOSITION FOR PROTECTION AGAINST FUNGAL ORGANISMS | March 2024 | July 2025 | Allow | 17 | 2 | 0 | No | No |
| 18402960 | SUSPENSIONS AND DILUENTS FOR METRONIDAZOLE AND BACLOFEN | January 2024 | July 2025 | Allow | 18 | 2 | 0 | No | No |
| 18392543 | HYDROGEL DRUG DELIVERY SYSTEMS FOR THE TREATMENT OF PEDIATRIC GROWTH PLATE INJURIES | December 2023 | May 2025 | Allow | 16 | 1 | 1 | Yes | No |
| 18532596 | MODIFIED-RELEASE DOSAGE FORMS OF RUXOLITINIB | December 2023 | August 2024 | Abandon | 9 | 1 | 0 | No | No |
| 18522062 | ORAL PATCH FOR TREATING MOUTH ULCERS | November 2023 | August 2024 | Allow | 8 | 2 | 0 | Yes | No |
| 18385589 | 10-(2-HYDROXYETHYL)-9-(2-HYDROXYPYRIDIN-3-YL)-3,4,6,7,9,10-HEXAHYDROACRIDINE-1,8(2H,5H)-DIONE AS AN ANTIMICROBIAL COMPOUND | October 2023 | March 2024 | Allow | 5 | 1 | 0 | No | No |
| 18496388 | Anti-Dandruff Composition | October 2023 | October 2025 | Allow | 24 | 2 | 0 | No | No |
| 18383987 | PH STABILIZED TOPICAL OPHTHALMIC COMPOSITIONS | October 2023 | February 2026 | Abandon | 28 | 4 | 0 | No | No |
| 18372162 | Therapeutic Composition and Methods | September 2023 | October 2024 | Allow | 13 | 1 | 1 | No | No |
| 18244734 | COMPOSITION AND THERAPY FOR TREATMENT OF GAG REFLEXES | September 2023 | February 2026 | Abandon | 29 | 3 | 1 | No | No |
| 18461665 | PHARMACEUTICAL FORMULATIONS OF PHLOROGLUCINOL AND TRIMETHYLPHLOROGLUCINOL | September 2023 | February 2026 | Abandon | 30 | 1 | 0 | No | No |
| 18240528 | ODOR ELIMINATING COMPOSITION WITH MORPHOLINIUM AND ALGINATE COMPOUNDS | August 2023 | February 2026 | Abandon | 30 | 1 | 0 | No | No |
| 18238743 | COMPOSITIONS COMPRISING WATER THAT EXHIBITS INCREASED CELL PERMEABILITY AND METHODS OF USE THEREOF | August 2023 | October 2024 | Abandon | 14 | 2 | 0 | No | No |
| 18269379 | PHARMACEUTICAL COMPOSITION COMPRISING TADALAFIL OR PHARMACEUTICALLLY ACCEPTABLE SALT THEREOF AND DUTASTERIDE OR PHARMACEUTICALLLY ACCEPTABLE SALT THEREOF EXHIBITING NOVEL DISSOLUTION RATE | June 2023 | February 2026 | Allow | 32 | 1 | 0 | No | No |
| 18339972 | PREPARATION METHOD OF AMISULPRIDE TABLET | June 2023 | February 2026 | Allow | 32 | 1 | 0 | No | No |
| 18335575 | FIBROUS PELLET FOR ORAL APPLICATIONS AND METHODS THEREOF | June 2023 | January 2026 | Abandon | 32 | 1 | 0 | No | No |
| 18199974 | Oleogel having a protein microstructure with optimized oil release properties for replacing structured fats and saturated oils in food and cosmetic products | May 2023 | November 2023 | Allow | 5 | 1 | 0 | Yes | No |
| 18321644 | VAGINAL CARE COMPOSITIONS AND METHODS OF IMPROVING VAGINAL HEALTH | May 2023 | November 2023 | Allow | 6 | 2 | 0 | Yes | No |
| 18304269 | CURCUMINOID COMPOSITES | April 2023 | October 2025 | Allow | 30 | 1 | 0 | No | No |
| 18297135 | Personal Care Compositions | April 2023 | April 2024 | Allow | 12 | 2 | 0 | No | No |
| 18248218 | ANTIPERSPIRANT COMPOSITION | April 2023 | December 2025 | Allow | 32 | 2 | 0 | No | No |
| 18163912 | MANUFACTURING DEVICE FOR GELATIN CAPSULE | February 2023 | March 2026 | Allow | 37 | 1 | 0 | No | No |
| 18007282 | PHARMACEUTICAL FORMULATIONS COMPRISING TADALAFIL | January 2023 | February 2026 | Allow | 37 | 1 | 0 | No | No |
| 18151382 | PHARMACEUTICAL COMPOSITION COMPRISING EICOSAPENTAENOIC ACID AND DERIVATIVES THEREOF AND A STATIN | January 2023 | February 2025 | Abandon | 25 | 2 | 0 | No | No |
| 18009554 | HAEMOSTATIC MATERIAL | December 2022 | July 2025 | Abandon | 31 | 1 | 0 | No | No |
| 18075150 | MODIFIED-RELEASE DOSAGE FORMS OF RUXOLITINIB | December 2022 | January 2024 | Abandon | 13 | 2 | 0 | No | No |
| 18060929 | PHARMACEUTICAL FORMULATION | December 2022 | August 2024 | Abandon | 21 | 2 | 0 | No | No |
| 17994720 | Therapeutic Composition And Methods | November 2022 | September 2023 | Allow | 9 | 1 | 0 | No | No |
| 17987929 | PHARMACEUTICAL COMPOSITIONS CONTAINING MIXED POLYMERIC MICELLES | November 2022 | December 2023 | Allow | 13 | 1 | 0 | No | No |
| 17924781 | PERCUTANEOUS ABSORPTION PREPARATION COMPRISING DONEPEZIL WITH IMPROVED STABILITY | November 2022 | October 2025 | Allow | 35 | 1 | 0 | No | No |
| 17924202 | FIBROUS LAYER HAVING HYDROPHILIC PROPERTIES AND A FABRIC COMPRISING SUCH LAYER | November 2022 | November 2025 | Abandon | 36 | 0 | 1 | No | No |
| 17980516 | OXYGEN GENERATING FACE MASKS | November 2022 | November 2023 | Abandon | 13 | 1 | 0 | No | No |
| 17979506 | THERMO-RESPONSIVE HYDROGEL FOR INTRATUMORAL ADMINISTRATION AS A TREATMENT IN SOLID TUMOR CANCERS | November 2022 | January 2025 | Allow | 27 | 3 | 0 | No | No |
| 17969554 | ANTIBIOTIC FORMULATIONS FOR LOWER BACK PAIN | October 2022 | August 2024 | Allow | 22 | 2 | 0 | Yes | No |
| 17995748 | GRANULES COMPRISING SURFACE-REACTED CALCIUM CARBONATE AS EXCIPIENT | October 2022 | October 2025 | Abandon | 37 | 0 | 1 | No | No |
| 17916903 | VISCOUS COMPOSITION | October 2022 | September 2025 | Abandon | 35 | 1 | 0 | No | No |
| 17937660 | COMPOSITION AND THERAPY FOR TREATMENT OF GAG REFLEXES | October 2022 | March 2023 | Allow | 5 | 1 | 0 | No | No |
| 17937665 | COMPOSITION AND THERAPY FOR TREATMENT OF GAG REFLEXES | October 2022 | June 2023 | Allow | 9 | 2 | 0 | Yes | No |
| 17947711 | Compositions Containing Verteporfin, Ribavirin, Gemcitabine, or Combinations Thereof and Methods of Use for Treating COVID-19, Cancer, or Non Cancer Diseases | September 2022 | October 2023 | Allow | 13 | 2 | 0 | No | No |
| 17802314 | WASH COMPOSITION SUBSTANTIALLY FREE OF OIL | August 2022 | June 2025 | Allow | 34 | 2 | 0 | No | No |
| 17888611 | SUSPENSIONS AND DILUENTS FOR METRONIDAZOLE AND BACLOFEN | August 2022 | April 2024 | Abandon | 20 | 3 | 0 | No | No |
| 17888737 | SUSPENSIONS AND DILUENTS FOR METRONIDAZOLE AND BACLOFEN | August 2022 | April 2024 | Abandon | 20 | 3 | 0 | No | No |
| 17884496 | FOAMING BODY DEODORIZER | August 2022 | January 2024 | Abandon | 17 | 1 | 0 | No | No |
| 17760269 | DISSOLVING AGENT | August 2022 | June 2025 | Abandon | 34 | 1 | 0 | No | No |
| 17882223 | SUSPENSIONS AND DILUENTS FOR METRONIDAZOLE AND BACLOFEN | August 2022 | March 2024 | Abandon | 19 | 3 | 0 | No | No |
| 17881785 | SUSPENSIONS AND DILUENTS FOR METRONIDAZOLE AND BACLOFEN | August 2022 | March 2024 | Abandon | 19 | 4 | 0 | Yes | No |
| 17760108 | DEODORANT | August 2022 | September 2025 | Allow | 38 | 2 | 0 | Yes | No |
| 17879267 | Method of treating urolithiasis | August 2022 | November 2023 | Allow | 16 | 2 | 0 | No | No |
| 17879285 | Methods of manufacturing microspheres | August 2022 | July 2023 | Allow | 12 | 1 | 0 | No | No |
| 17815019 | LIQUID ORAL PHARMACEUTICAL DOSAGE FORM | July 2022 | May 2024 | Abandon | 21 | 2 | 0 | No | No |
| 17815046 | WOOD TREATMENT SOLUTIONS CONTAINING FUNGICIDES AND TERTIARY ALKANOLAMINES AND RELATED METHODS, WOOD PRODUCTS AND COMPOSITION FOR PROTECTION AGAINST FUNGAL ORGANISMS | July 2022 | January 2024 | Allow | 18 | 2 | 0 | No | No |
| 17864695 | COMPOSITION FOR LIP PAIN RELIEF AND METHOD OF MAKING | July 2022 | December 2024 | Abandon | 29 | 2 | 0 | No | No |
| 17809661 | METHOD FOR REMOVING KERATOTIC PLUGS | June 2022 | January 2024 | Allow | 18 | 2 | 0 | Yes | No |
| 17786198 | GEL COMPOSITIONS FOR MITIGATION OF BURN INJURIES, KITS CONTAINING THE GEL COMPOSITIONS, AND ASSOCIATED METHODS | June 2022 | September 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17832263 | METHODS FOR PREVENTING AND TREATING RESPIRATORY INFECTIONS VIA MODIFICATION OF VIRUS RECEPTOR BINDING DOMAINS USING HYPOHALOUS ACIDS | June 2022 | September 2025 | Abandon | 39 | 3 | 0 | No | No |
| 17743262 | Personal Care Compositions | May 2022 | June 2024 | Allow | 25 | 3 | 0 | No | No |
| 17776486 | COMPOSITION FOR ANTIMICROBIAL PHOTODYNAMIC THERAPY | May 2022 | October 2025 | Abandon | 41 | 1 | 1 | No | No |
| 17739862 | Process for the preparation of angiotensin receptor blockers or pharmaceutically acceptable salts thereof | May 2022 | November 2022 | Allow | 6 | 1 | 0 | No | No |
| 17775071 | ANTIPERSPIRANT FORMULATIONS COMPRISING HEMISQUALANE | May 2022 | May 2025 | Abandon | 36 | 4 | 0 | No | No |
| 17736291 | SUSPENSIONS AND DILUENTS FOR METRONIDAZOLE AND BACLOFEN | May 2022 | September 2023 | Abandon | 16 | 3 | 0 | Yes | No |
| 17735667 | SPRAYABLE COSMETIC COMPOSITION COMPRISING POLYGLYCEROL ESTERS | May 2022 | September 2023 | Abandon | 17 | 1 | 0 | No | No |
| 17734193 | FOAM COMPOSITIONS | May 2022 | March 2025 | Abandon | 34 | 4 | 0 | No | No |
| 17734188 | FOAM COMPOSITIONS | May 2022 | November 2025 | Allow | 42 | 6 | 0 | Yes | No |
| 17730500 | PERSONAL CARE COMPOSITIONS WITH CYSTINE | April 2022 | January 2023 | Allow | 9 | 0 | 0 | No | No |
| 17727510 | COMPOSITIONS COMPRISING INDIGO AND/OR AN INDIGO DERIVATIVE AND METHODS OF USE THEREOF | April 2022 | February 2025 | Abandon | 34 | 4 | 0 | No | No |
| 17725923 | SUSPENSIONS AND DILUENTS FOR METRONIDAZOLE AND BACLOFEN | April 2022 | June 2022 | Allow | 2 | 0 | 0 | No | No |
| 17719283 | Gel Texturizer Base for Cosmetics | April 2022 | July 2024 | Allow | 27 | 2 | 0 | No | No |
| 17640923 | A METHOD OF PREPARING POLYMERIC MICROPARTICLES, POLYMERIC MICROPARTICLES, MEDICAL COMPOSITION, COSMETIC COMPOSITION, MEDICAL ARTICLES AND COSMETIC ARTICLES USING THE SAME | March 2022 | February 2025 | Allow | 35 | 1 | 0 | No | No |
| 17640448 | FOOD COMPOSITIONS FOR LACTATING WOMEN | March 2022 | April 2025 | Abandon | 37 | 1 | 0 | No | No |
| 17686198 | UNDERARM TONER | March 2022 | September 2023 | Allow | 19 | 2 | 0 | Yes | No |
| 17682033 | RESPIRATORY TRACT DELIVERY OF LEVODOPA AND DOPA DECARBOXYLASE INHIBITOR FOR TREATMENT OF PARKINSON'S DISEASE | February 2022 | February 2023 | Allow | 12 | 1 | 0 | Yes | No |
| 17681705 | HYDROGEN SULFIDE AND NITRIC OXIDE THERAPY FOR COVID-19 INFECTION | February 2022 | November 2024 | Abandon | 33 | 1 | 1 | No | No |
| 17635342 | METHOD FOR THE DECOLORIZATION OF KERATIN MATERIAL THAT HAS BEEN DYED USING AN ORGANOSILICON COMPOUND AND A PIGMENT | February 2022 | May 2025 | Abandon | 39 | 1 | 0 | No | No |
| 17665313 | IODINE COMPOSITIONS | February 2022 | July 2023 | Allow | 17 | 2 | 0 | Yes | No |
| 17632174 | Oral Care Compositions and Methods of Use | February 2022 | January 2026 | Allow | 48 | 3 | 0 | Yes | No |
| 17632182 | Compositions and Related Methods | February 2022 | January 2026 | Allow | 47 | 3 | 0 | No | No |
| 17625688 | ANTIBACTERIAL GLASS COMPOSITION AND MANUFACTURING METHOD THEREOF | January 2022 | July 2025 | Allow | 42 | 2 | 0 | No | No |
| 17553425 | NO-RINSE MAKEUP REMOVAL COMPOSITION | December 2021 | May 2024 | Allow | 29 | 2 | 0 | No | No |
| 17619324 | Ruthenium (II) Complexes and Conjugates Thereof for Use as Photosensitizer Agent in Photodynamic Therapy | December 2021 | January 2026 | Allow | 49 | 2 | 1 | No | No |
| 17549491 | METHOD FOR USING MUSTARD MEAL OR AN EXTRACT THEREOF | December 2021 | January 2025 | Abandon | 37 | 1 | 0 | No | No |
| 17547045 | SILICONE OIL-FREE ANTIPERSPIRANTS | December 2021 | November 2023 | Abandon | 23 | 2 | 0 | No | No |
| 17614156 | EXTERNAL PREPARATION | November 2021 | November 2024 | Abandon | 36 | 1 | 0 | No | No |
| 17534752 | ATTRACTANTS FOR RATS | November 2021 | January 2023 | Allow | 14 | 3 | 0 | No | No |
| 17613670 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HBV | November 2021 | February 2025 | Abandon | 38 | 0 | 1 | No | No |
| 17607053 | ETHANOL HARDENER AND USE THEREOF | October 2021 | November 2024 | Allow | 37 | 1 | 1 | No | No |
| 17452227 | SELF-EMULSIFYING FORMULATION OF BISPHOSPHONATES AND ASSOCIATED DOSAGE FORMS | October 2021 | August 2024 | Abandon | 34 | 1 | 0 | No | No |
| 17605418 | PREBIOTIC SKIN CARE COMPOSITIONS CONTAINING CARBOXYLIC ACIDS | October 2021 | December 2024 | Allow | 38 | 2 | 0 | No | No |
| 17603015 | LIPID PHARMACEUTICAL PREPARATION AND APPLICATION THEREOF | October 2021 | May 2025 | Allow | 43 | 1 | 0 | No | No |
| 17603163 | NEW DELIVERY SYSTEM FOR POLYUNSATURATED FATTY ACIDS | October 2021 | August 2025 | Allow | 46 | 2 | 0 | No | Yes |
| 17496056 | CARE COMPOSITION AND USE THEREOF | October 2021 | May 2025 | Allow | 43 | 3 | 0 | Yes | No |
| 17601545 | DENTAL COMPOSITION | October 2021 | February 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17491651 | METHODS OF MAKING AND USING COMPOSITIONS COMPRISING FLAVONOIDS | October 2021 | December 2025 | Abandon | 50 | 1 | 1 | No | No |
| 17472551 | PREPARATION FOR TREATING BODY ODOR | September 2021 | January 2025 | Abandon | 40 | 4 | 0 | No | No |
| 17446663 | Compressible Cannabinoid Pharmaceutical Composition | September 2021 | December 2024 | Abandon | 39 | 1 | 0 | No | No |
| 17409003 | ORAL PHARMACEUTICAL COMPOSITIONS OF LOSARTAN OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | August 2021 | December 2022 | Abandon | 16 | 3 | 0 | Yes | No |
| 17423350 | AN ANTIMICROBIAL MIXTURE | July 2021 | July 2025 | Abandon | 48 | 3 | 0 | Yes | No |
| 17305357 | FOAMING MIXED ALCOHOL/WATER COMPOSITIONS COMPRISING A STRUCTURED ALKOXYLATED SILOXANE | July 2021 | July 2025 | Allow | 48 | 5 | 0 | No | No |
| 17354181 | Natural Hydrocarbon/Ester Compositions with Improved Sensory Properties | June 2021 | August 2025 | Allow | 50 | 5 | 0 | Yes | No |
| 17415272 | AN ANTIPERSPIRANT COMPOSITION COMPRISING INORGANIC POLYIONIC CLUSTER | June 2021 | October 2024 | Allow | 40 | 2 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner LEE, SIN J.
With a 40.0% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 25.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner LEE, SIN J works in Art Unit 1613 and has examined 313 patent applications in our dataset. With an allowance rate of 62.3%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 32 months.
Examiner LEE, SIN J's allowance rate of 62.3% places them in the 22% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by LEE, SIN J receive 2.63 office actions before reaching final disposition. This places the examiner in the 77% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by LEE, SIN J is 32 months. This places the examiner in the 49% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +23.2% benefit to allowance rate for applications examined by LEE, SIN J. This interview benefit is in the 69% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 18.8% of applications are subsequently allowed. This success rate is in the 18% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 42.5% of cases where such amendments are filed. This entry rate is in the 65% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 66.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 52% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 68.8% of appeals filed. This is in the 54% percentile among all examiners. Of these withdrawals, 72.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 69.4% are granted (fully or in part). This grant rate is in the 76% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 1.0% of allowed cases (in the 67% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 0% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.